{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:56:01Z","timestamp":1768035361448,"version":"3.49.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":3704,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.farma.2011.02.010","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T22:36:02Z","timestamp":1312583762000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Consideraciones espec\u00edficas en la prescripci\u00f3n e intercambio terap\u00e9utico de estatinas"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Garc\u00eda-Sabina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gul\u00edn-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sempere-Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mart\u00ednez-Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2011.02.010_bib0005","first-page":"541","article-title":"The Statins in Preventive Cardiology","volume":"29","author":"Steinberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2011.02.010_bib0010","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.farma.2011.02.010_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","article-title":"Beyond lipid lowering: the role of statins in vascular protection","volume":"86","author":"Liao","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.farma.2011.02.010_bib0025","unstructured":"Lou Arnal S, Rodr\u00edguez Roca G. Displipemias. Factores de riesgo cardiovacular. Documentos cl\u00ednicos SEMERGEN. 2005; 23-35 [citado 15 Ene 2011]. Disponible en: http:\/\/www.semergen.es\/semergen\/contentFiles\/13693\/es\/dislipemias.pdf."},{"key":"10.1016\/j.farma.2011.02.010_bib0030","unstructured":"Su\u00e1rez Fern\u00e1ndez C. Protocolos de riesgo cardiovascular de la SEMI. 2004; 18-19 [citado 15 Ene 2011]. Disponible en: http:\/\/www.fesemi.org\/grupos\/riesgo_c\/publicaciones\/protocolos_riesgo_vascular.pdf."},{"key":"10.1016\/j.farma.2011.02.010_bib0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2009.05.020","article-title":"Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"104","author":"Cui","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.farma.2011.02.010_bib0040","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.farma.2011.02.010_bib0045","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","article-title":"Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia","volume":"55","author":"Juridique","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.farma.2011.02.010_bib0050","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.farma.2011.02.010_bib0055","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1067\/mhj.2002.129312","article-title":"Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial","volume":"144","author":"Brown","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.farma.2011.02.010_bib0060","first-page":"4","article-title":"Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials","author":"Edwards","year":"2003","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.farma.2011.02.010_bib0065","series-title":"Ayuda en la toma de decisiones farmacoterap\u00e9uticas","author":"Garc\u00eda Sabina","year":"2009"},{"key":"10.1016\/j.farma.2011.02.010_bib0070","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1345\/aph.1D391","article-title":"Approximate equivalent rosuvastatin doses for temporary statin interchange programs","volume":"38","author":"Kendrach","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.farma.2011.02.010_bib0075","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(24)29609-9","article-title":"Human liver-specific organic anion transporter. LST-1, mediates uptake of pravastatin by human hepatocytes","volume":"297","author":"Nakai","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0080","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.farma.2011.02.010_bib0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002280100329","article-title":"Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)","volume":"57","author":"Igel","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14622416.1.2.125","article-title":"Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment","volume":"1","author":"Brockmoller","year":"2000","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.farma.2011.02.010_bib0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0100","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1124\/jpet.105.085589","volume":"314","author":"Matsushima","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","article-title":"Pitavastatin \u2013 pharmacological profile from early phase studies","volume":"11","author":"Catapano","year":"2010","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.farma.2011.02.010_bib0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2133\/dmpk.DMPK-10-RG-073","article-title":"Intestinal Absorption of HMG-CoA Reductase Inhibitor Pitavastatin Mediated by Organic Anion Transporting Polypeptide and P-Glycoprotein\/Multidrug Resistance 1","volume":"26","author":"Shirasaka","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.farma.2011.02.010_bib0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.farma.2011.02.010_bib0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/CCLM.2003.087","article-title":"Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine","volume":"41","author":"Oscarson","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.farma.2011.02.010_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2009.54","article-title":"The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy","volume":"10","author":"Romaine","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.farma.2011.02.010_bib0130","first-page":"1281","article-title":"Drug interactions and the statins","volume":"161","author":"Herman","year":"1999","journal-title":"CMAJ"},{"key":"10.1016\/j.farma.2011.02.010_bib0135","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.farma.2011.02.010_bib0140","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","article-title":"Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations","volume":"68","author":"Kyrklund","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0145","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","article-title":"Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid","volume":"59","author":"Ucar","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0150","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.farma.2011.02.010_bib0155","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1023\/A:1011036428972","article-title":"HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein","volume":"18","author":"Wang","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.farma.2011.02.010_bib0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0165","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/00498250701278442","article-title":"Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1","volume":"37","author":"Nakagomi-Hagihara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.farma.2011.02.010_bib0170","unstructured":"COF Navarra. Cerivastatina: reflexiones sobre su retirada. Boletin Informativo de Farmacovigilancia. N\u00famero 22 [citado 15 Ene 2011]. Disponible en: http:\/\/www.cfnavarra.es\/bif\/DEFAULT.HTML."},{"key":"10.1016\/j.farma.2011.02.010_bib0175","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2165\/00003495-200464100-00003","article-title":"Management of hyperlipidaemia associated with heart transplantation","volume":"64","author":"Wenke","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.farma.2011.02.010_bib0180","unstructured":"Ficha t\u00e9cnica de Lymetel\u00ae (fluvastatina), texto actualizado Mayo 2007. Lab ANDROMACO, S.A."},{"key":"10.1016\/j.farma.2011.02.010_bib0185","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-004-0858-5","article-title":"Rhabdomyolysis in a patient receiving atorvastatin and fluconazole","volume":"60","author":"Kahri","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0190","first-page":"444","article-title":"Rhabdomyolysis induced by simvastatin-fluconazole combination","volume":"100","author":"Hazin","year":"2008","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.farma.2011.02.010_bib0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002280000127","article-title":"Effect of fluconazole on plasma fluvastatin and pravastatin concentrations","volume":"56","author":"Kantola","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0200","unstructured":"Ficha t\u00e9cnica de Alcosin\u00ae (simvastatina), texto actualizado Abril 2006. Industria Qu\u00edmica Farmac\u00e9utica VIR, S.A."},{"key":"10.1016\/j.farma.2011.02.010_bib0205","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.farma.2011.02.010_bib0210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.1998.00034.x","article-title":"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin","volume":"46","author":"Kivist\u00f6","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","article-title":"Effect of itraconazole on the pharmacokinetics of atorvastatin","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0225","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1067\/mcp.2000.110537","article-title":"Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin","volume":"68","author":"Mazzu","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0009-9236(96)90167-8","article-title":"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid","volume":"60","author":"Neuvonen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0235","unstructured":"Informaci\u00f3n t\u00e9cnica de Pravastatin; texto actualizado Marzo 2008. Mylan Pharmaceuticals Inc (Morgantown, WV \u2013EE.UU.-)."},{"key":"10.1016\/j.farma.2011.02.010_bib0240","unstructured":"Ficha t\u00e9cnica de Zarator\u00ae (atorvastatina), texto actualizado Julio 2010. Lab PARKE-DAVIS, S.L. (Grupo Pfizer)."},{"key":"10.1016\/j.farma.2011.02.010_bib0245","unstructured":"Ficha t\u00e9cnica de Lovastatina-Normon\u00ae, texto actualizado Mayo 2005. Lab NORMON S.A."},{"key":"10.1016\/j.farma.2011.02.010_bib0250","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.farma.2011.02.010_bib0255","unstructured":"Informaci\u00f3n t\u00e9cnica de Noxafil\u00ae susp (posaconazol); texto actualizado\u00a0Septiembre 2010. Schering Corporation.(Kenilworth, NJ-USA)."},{"key":"10.1016\/j.farma.2011.02.010_bib0260","unstructured":"Ficha t\u00e9cnica de VFEND\u00ae (voriconazol), texto actualizado 22 Marzo 2006. Lab Pfizer Limited."},{"key":"10.1016\/j.farma.2011.02.010_bib0265","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.farma.2011.02.010_bib0270","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-009-5078-6","article-title":"Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin","volume":"256","author":"Wagner","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.farma.2011.02.010_bib0275","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/106002809703100710","article-title":"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin","volume":"31","author":"Grunden","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.farma.2011.02.010_bib0280","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/00912700222011373","article-title":"A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers","volume":"42","author":"Amsden","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0285","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/009127009903900510","article-title":"Erythromycin coadministration increases plasma atorvastatin concentrations","volume":"39","author":"Siedlik","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0290","first-page":"213","article-title":"Rhabdomyolysis associated with lovastatin and erythromycin use","volume":"154","author":"Spach","year":"1991","journal-title":"West J Med"},{"key":"10.1016\/j.farma.2011.02.010_bib0295","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","article-title":"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0300","unstructured":"Ficha t\u00e9cnica de Alipza\u00ae (pitavastatina), texto actualizado Julio 2010. Lab Kowa Pharmaceutical Europe Co. Ltd."},{"key":"10.1016\/j.farma.2011.02.010_bib0305","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1185\/030079905X65466","article-title":"Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections","volume":"21","author":"Ciervo","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.farma.2011.02.010_bib0310","unstructured":"Ficha t\u00e9cnica de Ketek\u00ae (telitromicina), texto actualizado 31 Mayo 2010. Lab Aventis Pharma, S.A."},{"key":"10.1016\/j.farma.2011.02.010_bib0315","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(98)90067-4","article-title":"The interaction of diltiazem with lovastatin and pravastatin","volume":"64","author":"Azie","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0320","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1345\/aph.1A481","article-title":"Rhabdomyolysis with concurrent atorvastatin and diltiazem","volume":"36","author":"Lewin","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.farma.2011.02.010_bib0325","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in seronegative volunteers: ACTG Study A5047","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.farma.2011.02.010_bib0330","unstructured":"Ficha t\u00e9cnica de Kaletra\u00ae (lopinavir\/ritonavir), texto actualizado 7 Octubre 2008. Lab Abbott Laboratories Limited."},{"key":"10.1016\/j.farma.2011.02.010_bib0335","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00002018-200326060-00004","article-title":"Potentially significant drug interactions of class III antiarrhythmic drugs","volume":"26","author":"Yamreudeewong","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.farma.2011.02.010_bib0340","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.clpt.6100098","article-title":"Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics","volume":"81","author":"Becquemont","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0345","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1345\/aph.1D498","article-title":"Rhabdomyolysis in association with simvastatin and amiodarone","volume":"38","author":"Roten","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.farma.2011.02.010_bib0350","unstructured":"Ficha t\u00e9cnica de Trangorex\u00ae (amiodarona), texto actualizado Junio 2009. Lab SANOFI AVENTIS, S.A."},{"key":"10.1016\/j.farma.2011.02.010_bib0355","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1345\/aph.1C256","article-title":"Bosentan for the treatment of pulmonary arterial hypertension","volume":"37","author":"Kenyon","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.farma.2011.02.010_bib0360","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00003088-200342030-00004","article-title":"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin","volume":"42","author":"Dingemanse","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.farma.2011.02.010_bib0365","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","article-title":"Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid","volume":"59","author":"Ucar","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0370","first-page":"2732","article-title":"Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients","volume":"25","author":"Regazzi","year":"1993","journal-title":"Transplant Proc"},{"key":"10.1016\/j.farma.2011.02.010_bib0375","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clpt.2003.09.011","article-title":"Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression","volume":"75","author":"Hedman","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0380","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003495-200363040-00003","article-title":"Interactions between cyclosporin and lipidlowering drugs: implications for organ transplant recipients","volume":"63","author":"\u00c5sberg","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.farma.2011.02.010_bib0385","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0390","first-page":"381","article-title":"The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine","volume":"19","author":"Hasunuma","year":"2003","journal-title":"J Clin Ther Med"},{"key":"10.1016\/j.farma.2011.02.010_bib0395","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.farma.2011.02.010_bib0400","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000187521","article-title":"Plasma concentration profiles of simvastatin 3-hydroxy- 3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin","volume":"65","author":"Arnadottir","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.farma.2011.02.010_bib0405","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","article-title":"Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus","volume":"158","author":"Ichimaru","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.farma.2011.02.010_bib0410","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/107424840100600404","article-title":"Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A","volume":"6","author":"Park","year":"2001","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0415","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/01.smj.0000251470.39036.ea","article-title":"Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin","volume":"99","author":"Khandwala","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.farma.2011.02.010_bib0420","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.75.884.359","article-title":"Efficacy of statin therapy: possible effect of phenytoin","volume":"75","author":"Murphy","year":"1999","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.farma.2011.02.010_bib0425","unstructured":"Informaci\u00f3n t\u00e9cnica de Lovastatin; texto actualizado\u00a0Enero 2008. Mylan Pharmaceuticals Inc. (Morgantown, WV \u2013EE.UU-)."},{"key":"10.1016\/j.farma.2011.02.010_bib0430","unstructured":"Informaci\u00f3n t\u00e9cnica de Simvastatin; texto actualizado\u00a0Septiembre 2006. Ranbaxy Pharmaceuticals Inc.(Jacksonville, FL \u2013EE.UU.-)."},{"key":"10.1016\/j.farma.2011.02.010_bib0435","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","article-title":"Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites","volume":"78","author":"Backman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0440","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0445","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mcp.2001.115542","article-title":"Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate","volume":"69","author":"Kyrklund","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0450","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0002-9149(05)80024-4","article-title":"Pharmacokinetics of the combination of fluvastatin and gemfibrozil","volume":"76","author":"Spence","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.farma.2011.02.010_bib0455","unstructured":"Ficha t\u00e9cnica de Trialmin; texto actualizado Mayo 2007. Lab Menarini SA."},{"key":"10.1016\/j.farma.2011.02.010_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjmed.2008.09.033","article-title":"Reduced efficacy of rosuvastatin by St. John's Wort","volume":"122","author":"Gordon","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.farma.2011.02.010_bib0465","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-007-0345-x","article-title":"Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia","volume":"63","author":"Andren","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0470","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/02813430701442768","article-title":"Effects of treatment with a commercially available St John's Wort product (Movina) on colesterol levels in patients with hypercholesterolemia treated with simvastatin","volume":"25","author":"Eggertsen","year":"2007","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.farma.2011.02.010_bib0475","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0009-9236(01)64092-X","article-title":"Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin","volume":"70","author":"Sugimoto","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0480","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O\u2019Brien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.farma.2011.02.010_bib0485","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-200140040-00003","article-title":"Clinical pharmacokinetics of fluvastatin","volume":"40","author":"Scripture","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.farma.2011.02.010_bib0490","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","article-title":"Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations","volume":"68","author":"Kyrklund","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0495","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2125.2003.01972.x","article-title":"Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects","volume":"57","author":"Kyrklund","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0500","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.farma.2011.02.010_bib0505","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1124\/jpet.103.061770","article-title":"Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay","volume":"308","author":"Lau","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0510","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1067\/mcp.2000.110216","article-title":"Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin","volume":"68","author":"Lilja","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0515","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0009-9236(98)90034-0","article-title":"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid","volume":"63","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0520","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0009-9236(99)90048-6","article-title":"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin","volume":"66","author":"Lilja","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0525","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2125.2005.02462.x","article-title":"Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin","volume":"60","author":"Ando","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0530","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2125.2003.02030.x","article-title":"Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese","volume":"57","author":"Fukazawa","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.farma.2011.02.010_bib0535","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/cp.1999.v66.a101208","article-title":"Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"66","author":"Rogers","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2011.02.010_bib0540","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/WNL.62.4.670","article-title":"Statin-associated rhabdomyolysis triggered by grapefruit consumption","volume":"62","author":"Dreier","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.farma.2011.02.010_bib0545","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00129784-200404050-00002","article-title":"Interactions between grapefruit juice and cardiovascular drugs","volume":"4","author":"Bailey","year":"2004","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113063431100122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113063431100122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:16:40Z","timestamp":1761106600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S113063431100122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S113063431100122X"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2011.02.010","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consideraciones espec\u00edficas en la prescripci\u00f3n e intercambio terap\u00e9utico de estatinas","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2011.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 SEFH. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}